Ginkgo Bioworks Holdings annual shares outstanding
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings Shares Outstanding History (DNA)
Ginkgo Bioworks Holdings reported 58.2M shares outstanding at the end of fiscal 2025.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 58.2M | 3.8M | +7.07% |
| 2024 | 2024-12-31 | 54.4M | 4.3M | +8.66% |
| 2023 | 2023-12-31 | 50.0M | 48.9M | +4131.16% |
| 2022 | 2022-12-31 | 1.2M | 175,364.905 | +17.41% |
| 2021 | 2021-12-31 | 1.0M | 201,747.673 | +25.05% |
| 2020 | 2020-12-31 | 805,372.423 | — | — |
Ginkgo Bioworks Holdings quarterly shares outstanding
Q4.20
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 63.7M | 8.3M | +14.95% |
| Q1 2026 | 2026-03-31 | 61.7M | 7.0M | +12.73% |
| Q4 2025 | 2025-12-31 | 58.2M | 3.8M | +7.07% |
| Q3 2025 | 2025-09-30 | 56.8M | 3.8M | +7.07% |
| Q2 2025 | 2025-06-30 | 55.4M | 54.1M | +4166.08% |
| Q1 2025 | 2025-03-31 | 54.7M | 53.4M | +4203.51% |
| Q4 2024 | 2024-12-31 | 54.4M | 4.3M | +8.66% |
| Q3 2024 | 2024-09-30 | 53.1M | 51.8M | +4205.27% |
| Q2 2024 | 2024-06-30 | 1.3M | 77,520.625 | +6.35% |
| Q1 2024 | 2024-03-31 | 1.3M | 62,340 | +5.16% |
| Q4 2023 | 2023-12-31 | 50.0M | 48.9M | +4131.16% |
| Q3 2023 | 2023-09-30 | 1.2M | 202,788.61 | +19.69% |
| Q2 2023 | 2023-06-30 | 1.2M | 199,418.582 | +19.51% |
| Q1 2023 | 2023-03-31 | 1.2M | 194,891.153 | +19.22% |
| Q4 2022 | 2022-12-31 | 1.2M | 175,364.905 | +17.41% |
| Q3 2022 | 2022-09-30 | 1.0M | 100,968.979 | +10.87% |
| Q2 2022 | 2022-06-30 | 1.0M | — | — |
| Q1 2022 | 2022-03-31 | 1.0M | — | — |
| Q4 2021 | 2021-12-31 | 1.0M | 201,747.673 | +25.05% |
| Q3 2021 | 2021-09-30 | 929,195.536 | — | — |
| Q4 2020 | 2020-12-31 | 805,372.423 | — | — |
Ginkgo Bioworks Holdings Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Ginkgo Bioworks Holdings share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Ginkgo Bioworks Holdings used $0 to repurchase common stock in fy 2023. Across the latest 4 reported fiscal years, total share repurchases were $25.4M.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2023 | 2023-12-31 | $0 |
| 2022 | 2022-12-31 | $0 |
| 2021 | 2021-12-31 | $25.0M |
| 2019 | 2019-12-31 | $408,000 |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Ginkgo Bioworks Holdings shares outstanding trends
Over the last five fiscal years, Ginkgo Bioworks Holdings's shares outstanding moved from 805,372.423 to 58.2M, a change of 57.4M. The latest reported quarter, Q2 2026, shows 63.7M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ginkgo Bioworks Holdings source filings ↗Community posts
Ginkgo links laboratory data services with Lilly’s TuneLab platform
Ginkgo ($DNA) Bioworks entered an agreement to provide experimental data-generation services to companies using Lilly’s ($LLY) TuneLab AI drug-discovery platform. Its Datapoints offering will supply small-molecule and antibody developabilit ...
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...
